XML 57 R41.htm IDEA: XBRL DOCUMENT v3.24.3
Capital Stock and Stockholders' Deficit (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Equity [Abstract]    
Schedule of Preferred Stock and Common Stock   The following table summarizes details of Legacy Allurion Preferred Stock authorized, issued, and outstanding immediately prior to the Business Combination (in thousands, except share amounts):
    
Preferred Stock
Authorized (1)
    
Preferred Stock
Issued and
Outstanding
    
Carrying
Value
 
Series A Preferred Stock
     2,276,786        2,276,786      $ 1,542  
Series
A-1
Preferred Stock
     1,513,028        1,486,048        2,842  
Series B Preferred Stock
     2,298,929        2,245,515        5,253  
Series C Preferred Stock
     8,113,616        7,927,446        39,122  
Series
D-1
Preferred Stock
     1,684,565        842,283        9,614  
Series
D-2
Preferred Stock
     3,644,616        3,644,616        24,054  
Series
D-3
Preferred Stock
     1,498,348        1,498,348        14,789  
  
 
 
    
 
 
    
 
 
 
Total
     21,029,888        19,921,042      $ 97,216  
  
 
 
    
 
 
    
 
 
 
The number of shares of Common Stock that have been reserved for the potential conversion or exercise, as applicable, of the Company’s securities as of December 31, 2023, is as follows:
Outstanding options to purchase common stock
     3,886,038  
Restricted Stock Units
     643,635  
Warrants to purchase preferred stock (as converted to warrants to purchase common stock)
     138,857  
Warrants to purchase common stock
     264,801  
Public warrants to purchase common stock
     18,759,838  
Earn-Out
shares
     9,000,000  
  
 
 
 
Total
     32,693,169  
  
 
 
 
Summary of Warrants to Purchase the Classes of Preferred Stock and Common Stock Outstanding As of September 30, 2024, there were 403,658 Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified.
 
In connection with the Public Offering and Private Placement, we issued the Public Offering Warrants and Private Placement Warrants. As of September 30, 2024, there were 16,567,484 Public Offering Warrants and 2,260,159 Private Placement Warrants outstanding to purchase Common Stock.
 
September 30, 2024
 
Issuance Date
  
Remaining
Contractual Term
(in years)
    
Underlying Equity Instrument
  
Balance Sheet
Classification
    
Shares Issuable
Upon Exercise
of Warrant
    
Weighted
Average Exercise
Price
 
12/1/2014      0.2      Common Stock      Equity        44,272      $ 2.44  
3/30/2021      6.5      Common Stock      Liability        130,053        6.73  
9/15/2022      8.0      Common Stock      Liability        45,238        12.14  
6/4/2022      7.7      Common Stock      Liability        45,238        12.14  
1/17/2017      2.3      Common Stock      Equity        73,349        0.02  
8/3/2017      2.8      Common Stock      Equity        9,779        1.13  
9/8/2017      2.9      Common Stock      Liability        28,764        1.05  
6/19/2018      3.7      Common Stock      Liability        17,977        1.05  
6/25/2019      4.7      Common Stock      Liability        8,988        1.05  
7/1/2024      4.8      Common Stock      Liability        18,827,643        1.20  
           
 
 
    
              19,231,301     
           
 
 
    
 
December 31, 2023
 
Issuance Date
  
Remaining
Contractual Term
(in years)
    
Underlying Equity Instrument
  
Balance Sheet
Classification
    
Shares Issuable
Upon Exercise
of Warrant
    
Weighted
Average Exercise
Price
 
12/1/2014      0.9      Common Stock      Equity        44,272      $ 2.44  
3/30/2021      7.2      Common Stock      Liability        130,053        6.73  
9/15/2022      8.7      Common Stock      Liability        45,238        12.14  
6/4/2022      8.4      Common Stock      Liability        45,238        12.14  
1/17/2017      3.0      Common Stock      Equity        73,349        0.02  
8/3/2017      3.6      Common Stock      Equity        9,779        1.13  
9/8/2017      3.7      Common Stock      Liability        28,764        1.05  
6/19/2018      4.5      Common Stock      Liability        17,977        1.05  
6/25/2019      5.5      Common Stock      Liability        8,988        1.05  
           
 
 
    
              403,658     
           
 
 
    
As of December 31, 2023, there were 403,658 such Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified.
 
December 31, 2023
 
Issuance Date
  
Remaining
Contractual Term
(in years)
    
Underlying Equity Instrument
  
Balance Sheet
Classification
    
Shares Issuable
Upon Exercise
of Warrant
    
Weighted
Average Exercise
Price
 
12/1/2014
     0.9     
Common stock
  
 
Equity
 
     44,272      $ 2.44  
3/30/2021
     7.2     
Common stock
  
 
Liability
 
     130,053        6.73  
9/15/2022
     8.7     
Common stock
  
 
Liability
 
     45,238        12.14  
6/4/2022
     8.4     
Common stock
  
 
Liability
 
     45,238        12.14  
1/17/2017
     3.0     
Common stock
  
 
Equity
 
     73,349        0.02  
8/3/2017
     3.6     
Common stock
  
 
Equity
 
     9,779        1.13  
9/8/2017
     3.7     
Common stock
  
 
Liability
 
     28,764        1.05  
6/19/2018
     4.5     
Common stock
  
 
Liability
 
     17,977        1.05  
6/25/2019
     5.5     
Common stock
  
 
Liability
 
     8,988        1.05  
           
 
 
    
              403,658     
           
 
 
    
December 31, 2022
 
Issuance Date
  
Remaining
Contractual Term
(in years)
    
Underlying Equity Instrument
  
Balance Sheet
Classification
    
Shares Issuable
Upon Exercise
of Warrant
    
Weighted
Average Exercise
Price
 
4/1/2013      0.2      Series
A-1
Preferred Stock
     Liability        16,557      $ 1.95  
12/1/2014      1.9      Series B Preferred Stock      Liability        60,768        2.44  
3/30/2021      8.2      Series C Preferred Stock      Liability        130,053        6.73  
9/15/2022      9.7      Series
D-1
Preferred Stock
     Liability        45,238        12.14  
6/4/2022      9.4      Series
D-1
Preferred Stock
     Liability        45,238        12.14  
1/17/2017      4.0      Common stock      Liability        73,349        0.02  
8/3/2017      4.6      Common stock      Liability        9,779        1.13  
9/8/2017      4.7      Common stock      Liability        28,764        1.05  
6/19/2018      5.5      Common stock      Liability        17,977        1.05  
6/25/2019      6.5      Common stock      Liability        8,988        1.05  
           
 
 
    
              436,711